Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable XXXX in males and females.

@entity1 @entity135 @entity66 @entity5 @entity196 @entity3146
OBJECTIVE: The purpose of this study was to assess the consequences of a national immunization program with HPV vaccine for both @entity1 and @entity1 in Denmark, including the prophylactic effects on all potentially vaccine preventable @entity66 in male and female. METHODS: The study focussed on the quadrivalent vaccine which protects against @entity196 , 11, 16 and 18, and the vaccine's protection against genital warts, @entity3146 , cervical @entity5 (anal, @entity5 ) and @entity135 (oral cavity, oropharyngeal, hypopharyngeal and @entity5 ) were included in the analyses. In general, the analysis was performed in two phases. First, an agent-based transmission model that described the HPV transmission without and with HPV vaccination was applied. Second, an analysis of the incremental costs and effects was performed. The model did not include naturally-acquired immunity to HPV in the simulations. RESULTS: In the base case result (i.e. vaccination of @entity1 only, 85% vaccination rate, private market price at     123 per dose ex. VAT) an ICER of 3583    /QALY (3-dose regime) is estimated when all @entity66 are taken into account. Vaccination of @entity1 _ @entity1 vs. vaccination of @entity1 only an ICER of 28,031    /QALY (2-dose regime) and 41,636    /QALY (3-dose regime) is estimated. CONCLUSIONS: Extension of the current HPV programme in Denmark to include @entity1 and @entity1 is a cost effective preventive intervention that would lead to a faster prevention of @entity5 , @entity5 precursors and genital warts in @entity1 and @entity1 .
